Biocytogen (HKEX: 02315) is excited to attend World ADC San Diego 2024 at the Town & Country Resort, San Diego, CA, from November 4-7.
Our Business Development and Licensing Team looks forward to meeting you in person at Booth #208! We’ll also be showcasing two posters highlighting Biocytogen’s groundbreaking advancements in antibody-drug conjugate (ADC) projects. Don’t miss the chance to schedule a 1-on-1 meeting with us!
Exhibition Session:
Booth Number: #208
Poster Session:
Time: 6:30 p.m., Tuesday
Location: The Exhibition Hall
- Poster #31: Novel Bispecific ADC Targeting SEZ6 and B7H3 for the Treatment of Small Cell Lung Cancer (SCLC)
- Poster #32: BCG014: A CDH3-Targeting ADC with a Novel TOPO1 Inhibitor Payload
Antibody-drug conjugates (ADCs) significantly outperform traditional monoclonal antibody therapies by precisely targeting tumor cells and directly delivering cytotoxic agents. This targeted approach boosts therapeutic efficacy while minimizing toxicity to healthy cells, reducing side effects, and improving patient tolerability.
Building on these advantages, bispecific ADCs—which target two distinct tumor antigens—offer even greater targeting precision and efficacy. This dual targeting provides broader, more sustained cytotoxic activity against heterogeneous tumors. However, the complex structure of bispecific ADCs also introduces greater challenges in development and production.
To address these challenges, Biocytogen has independently developed the RenLite® platform, which leverages common light chain technology to effectively prevent mismatches between light and heavy chains during bispecific antibody assembly. In addition, Biocytogen owns the proprietary Linker & Payload platform BLD1102. Utilizing RenLite and the new bispecific ADC platform, we have generated a large antibody library against more than 200 tumor-associated antigens (TAAs) and established over 400 antibody discovery projects.
We look forward to discussing licensing opportunities for new antibody molecules and antibody discovery platforms with you.
Please click here to schedule a 1-on-1 meeting with us to learn more.
